Compare Gilead Sciences, Inc. (GILD) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Verizon Communications Inc — how do they compare? Gilead Sciences, Inc. trades at $136.45 (market cap $168.35B), while Verizon Communications Inc trades at $46.9 (market cap $196.40B). The key difference: Verizon Communications Inc is the larger of the two by market cap, and Verizon Communications Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.
| GILD | VZ | |
|---|---|---|
Market Cap | $168.35B | $196.40B |
Sector | Health | Media |
52-Week High | $155.80 | $51.38 |
52-Week Low | $110.56 | $38.40 |
Enterprise Value | $191.42B | $383.10B |
Dividend Yield | 2.42% | 5.99% |
Volume | — | 22,584,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Verizon (VZ) trades at $47.03, down 0.06% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $49.69. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.30 surpassing the $1.27 estimate. The company maintains strong cash flow from operations at $37.14 billion in 2025 and a healthy dividend yield, supported by a $0.71 per share payout scheduled for August 2026.
VZ presents a value opportunity with a low P/E of 12.31 and stable revenue around $138 billion, though competitive pressures from new entrants like SpaceX's Starlink and high debt levels pose risks. Analyst sentiment is mixed with 36.7% buy ratings, but fundamentals suggest resilience for income-focused investors seeking telecom exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
